References
- Palermo M, Quinkler M, Stewart PM. Apparent mineralocorticoid excess syndrome: An overview. Arq Bras Endocrinol Metabol. 2004;48:687–696.
- Mantero F, Palermo M, Petrelli MD, Tedde R, Stewart PM, Shackleton CHL. Apparent mineralocorticoid excess: Type I and type II. Steroids. 1996;61:193–196.
- Stewart PM. Mineralocorticoid hypertension. Lancet. 1999; 353:1341–1347.
- Melander O. Genetic factor in hypertension – What is known and what does it mean?. Blood Press. 2001;10:254–270.
- Giebisch GH, Wang WH. Potassium transport – An update. J Nephrol. 2010;23 (Suppl 16):S97–104.
- Armanini D, Lewicka S, Pratesi C, Scali M, Zennaro M, Zovato S, et al. Further studies on the mechanism of the mineralocorticoid action of licorice in humans. J Endocrinol Invest. 1996;19:624–629.
- Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994; 105:R11–R17.